东瑞制药2024 年报

Corporate Information公司資料 Group Structure本集團架構圖 Chairman’s Statement主席報告 Management Discussion and Analysis管理層討論及分析 Corporate Governance Report企業管治報告 Report of the Directors董事會報告 Independent Auditor’s Report獨立核數師報告 Consolidated Statement of Financial Position綜合財務狀況表 Consolidated Statement of Changes in Equity綜合權益變動表 Consolidated Statement of Cash Flows綜合現金流量表 Notes to Financial Statements財務報表附註 Five Year Financial Summary五年財務概要 Information for Shareholders股東資料 BOARD OF DIRECTORS 董事會 EXECUTIVE DIRECTORSMs. LI Kei Ling(Chairman)Mr. HUNG Yung Lai 李其玲女士（主席）熊融禮先生 NON-EXECUTIVE DIRECTORMr. LEUNG Hong Man 梁康民先生 勞同聲先生EDE, Ronald Hao Xi先生林明儀女士 INDEPENDENT NON-EXECUTIVE DIRECTORS Mr. LO Tung Sing TonyMr. EDE, Ronald Hao XiMs. LAM Ming Yee Joan CHIEF EXECUTIVE OFFICER 總裁 吳偉賢先生（於二零二四年九月十一日辭任）于麗偉女士（於二零二四年九月十三日獲委任） Mr. WU Weixian (Resigned on 11 September 2024)Ms. Yu Liwei (Appointed on 13 September 2024) 審核委員會 AUDIT COMMITTEE Mr. LO Tung Sing Tony(Chairman)Mr. EDE, Ronald Hao XiMs. LAM Ming Yee Joan 勞同聲先生（主席）EDE, Ronald Hao Xi先生林明儀女士 薪酬委員會 REMUNERATION COMMITTEE Mr. EDE, Ronald Hao Xi(Chairman)Ms. LI Kei LingMr. LO Tung Sing TonyMs. LAM Ming Yee Joan EDE, Ronald Hao Xi先生（主席）李其玲女士勞同聲先生林明儀女士 提名委員會 NOMINATION COMMITTEE Ms. LI Kei Ling(Chairman)Mr. LO Tung Sing TonyMr. EDE, Ronald Hao XiMs. LAM Ming Yee Joan 李其玲女士（主席）勞同聲先生EDE, Ronald Hao Xi先生林明儀女士 AUDITORS 核數師 Ernst & YoungCertified Public AccountantsRegistered Public Interest Entity Auditor 安永會計師事務所執業會計師註冊公眾利益實體核數師 主要往來銀行 PRINCIPAL BANKERS Bank of China (Hong Kong) Limited, Hong KongThe Hongkong and Shanghai Banking Corporation Limited, Hong KongIndustrial and Commercial Bank of China Suzhou Wuzhong Sub-BranchAgricultural Bank of China Suzhou Nanmen Sub-BranchBank of China Suzhou Wuzhong Sub-Branch 中國銀行（香港）有限公司，香港香港上海滙豐銀行有限公司，香港中國工商銀行蘇州市吳中支行中國農業銀行蘇州市南門支行中國銀行蘇州吳中支行 HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS 總辦事處及主要營業地點 Units 3001–02, 30/F, CNT Tower, 338 Hennessy Road,Wanchai, Hong Kong 香港灣仔軒尼詩道338號北海中心30樓3001–02室 註冊辦事處 REGISTERED OFFICE Cricket SquareHutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands Cricket SquareHutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands 主要股份過戶登記處 PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins Drive, P.O. Box 2681,Grand Cayman KY1-1111, Cayman Islands Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins Drive, P.O. Box 2681,Grand Cayman KY1-1111, Cayman Islands 香港股份過戶登記分處 HONG KONG BRANCH SHARE REGISTRAR ANDTRANSFER OFFICE 卓佳證券登記有限公司香港夏慤道16號遠東金融中心17樓 Tricor Investor Services Limited17/F, Far East Finance Centre,16 Harcourt Road, Hong Kong Group Structure As at 28 March 2025於二零二五年三月二十八日 致各股東： Dear SHAREHOLDERS, On behalf of the board (the “Board”) of the directors (the “Directors”) ofDawnrays Pharmaceutical (Holdings) Limited (the “Company”) and itssubsidiaries (collectively referred to as the “Group”). I’m pleased to presentthe results of the Group for the year ended 31 December 2024 (the“reporting period”). 本人欣然代表東瑞製葯（控股）有限公司（「本公司」）之董事（「董事」）會（「董事會」）提呈本公司及其附屬公司（統稱「本集團」）截至二零二四年十二月三十一日止年度（「報告期間」）之業績報告。 GROUP RESULTS 本集團業績 For the year ended 31 December 2024, the Group recorded revenueof approximately RMB1,060,309,000 (2023: RMB1,151,145,000),representing a decrease of 7.9% as compared with 2023. Profitattributable to owners of the parent was approximately RMB564,940,000(2023: RMB326,000,000), representing an increase of 73.3% as comparedwith 2023. 本集團截至二零二四年十二月三十一日止年度錄得收入約人民幣1,060,309,000元（二零二三年：人民幣1,151,145,000元），較二零二三年減少約7.9%。母公司擁有人應佔溢利約人民幣564,940,000元（二零二三年：人民幣326,000,000元），比二零二三年增加約73.3%。 母公司擁有人應佔溢利含出售於本集團賬面值為零元的35%康融東方（廣東）有限公司股權錄得淨收益約 人 民 幣277,627,000元（ 稅 前 人 民 幣286,670,000元）及善丰路廠區設備驗證政府補助淨收益約人民幣89,292,000元（稅前人民幣105,049,000元）所致；如撇除以上非經常性溢利約人民幣366,919,000元及出售股權前需分擔的康融東方（廣東）有限公司虧損人民 幣3,696,000元（二 零 二 三 年：人 民 幣40,933,000元 ）因 素， 母 公 司 擁 有 人 經 營 性 溢 利 為 人 民 幣201,717,000元（ 二 零 二 三 年： 人 民 幣249,954,000元），較二零二三年下降19.3%。主要原因是受「安」系列產品因集採影響銷售額下降；以及本公司間接全資擁有附屬公司蘇州東瑞製藥有限公司（「蘇州東瑞」）天靈路廠區及蘭州東瑞製藥有限公司（「蘭州東瑞」）廠區兩個項目搬遷完成，國內客戶和海外市場客戶需重新開展產品認證辦理供應商備案和海外註冊致原料藥及中間體銷量少，又因未達產致生產成本高企，產生存貨撥備達人民幣43,880,000元（二零二三年：人民幣10,936,000元），原料藥及中間體業務虧損人民幣60,975,000元（二零二三年：虧損人民幣32,692,000元）的影響。 Profit attributable to owners of the parent included a net gain ofRMB277,627,000 (before tax RMB286,670,000) from the disposal ofthe Group’s 35% equity interest in AD Pharmaceuticals Co., Ltd. with nilcarrying value, and the net gain of approximately RMB89,292,000 (beforetax RMB105,049,000) from the government subsidy for the verificationof the equipment in the factory at Shanfeng Road. Excluding the abovenon-recurring profit of approximately RMB366,919,000 and share aloss of RMB3,696,000 (2023: RMB40,933,000) on the investment in ADPharmaceutical Co., Ltd. before disposal, the operating profit attributableto owners of the parent amounted to approximately RMB201,717,000(2023: RMB249,954,000), representing a decrease of 19.3% as